SEC Filing Summary

Robert W. Postma, a director at Alaunos Therapeutics, Inc., acquired 21,829 shares of common stock on October 6, 2026, at a price of $0.7444 per share. This acquisition was made in lieu of board fees. Following this transaction, Postma directly owns 80,438 shares. Additionally, he has indirect ownership of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp., where he serves as principal.